238 related articles for article (PubMed ID: 16432270)
1. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
Ciraulo DA; Hitzemann RJ; Somoza E; Knapp CM; Rotrosen J; Sarid-Segal O; Ciraulo AM; Greenblatt DJ; Chiang CN
J Clin Pharmacol; 2006 Feb; 46(2):179-92. PubMed ID: 16432270
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.
Harris DS; Mendelson JE; Lin ET; Upton RA; Jones RT
Clin Pharmacokinet; 2004; 43(5):329-40. PubMed ID: 15080765
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
Compton P; Ling W; Moody D; Chiang N
Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the combination tablet of buprenorphine and naloxone.
Chiang CN; Hawks RL
Drug Alcohol Depend; 2003 May; 70(2 Suppl):S39-47. PubMed ID: 12738349
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms.
Chawarski MC; Moody DE; Pakes J; O'Connor PG; Schottenfeld RS
J Subst Abuse Treat; 2005 Dec; 29(4):307-12. PubMed ID: 16311183
[TBL] [Abstract][Full Text] [Related]
6. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects.
La Vincente SF; White JM; Somogyi AA; Bochner F; Chapleo CB
Clin Pharmacol Ther; 2008 Jan; 83(1):144-52. PubMed ID: 17568402
[TBL] [Abstract][Full Text] [Related]
7. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.
Middleton LS; Nuzzo PA; Lofwall MR; Moody DE; Walsh SL
Addiction; 2011 Aug; 106(8):1460-73. PubMed ID: 21395892
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine and naloxone interactions in methadone maintenance patients.
Mendelson J; Jones RT; Welm S; Brown J; Batki SL
Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of buprenorphine from crushed and whole buprenorphine (subutex) tablets.
Simojoki K; Lillsunde P; Lintzeris N; Alho H
Eur Addict Res; 2010; 16(2):85-90. PubMed ID: 20130408
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.
Harris DS; Jones RT; Welm S; Upton RA; Lin E; Mendelson J
Drug Alcohol Depend; 2000 Dec; 61(1):85-94. PubMed ID: 11064186
[TBL] [Abstract][Full Text] [Related]
12. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
Strain EC; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
[TBL] [Abstract][Full Text] [Related]
13. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers.
Mintzer MZ; Correia CJ; Strain EC
Drug Alcohol Depend; 2004 May; 74(2):205-9. PubMed ID: 15099664
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.
McAleer SD; Mills RJ; Polack T; Hussain T; Rolan PE; Gibbs AD; Mullins FG; Hussein Z
Drug Alcohol Depend; 2003 Oct; 72(1):75-83. PubMed ID: 14563545
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
[TBL] [Abstract][Full Text] [Related]
16. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Bickel WK; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR; Johnson RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):47-53. PubMed ID: 2459370
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
Dong R; Wang H; Li D; Lang L; Gray F; Liu Y; Laffont CM; Young M; Jiang J; Liu Z; Learned SM
Drugs R D; 2019 Sep; 19(3):255-265. PubMed ID: 31197606
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
19. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
Larance B; Lintzeris N; Ali R; Dietze P; Mattick R; Jenkinson R; White N; Degenhardt L
Drug Alcohol Depend; 2014 Mar; 136():21-7. PubMed ID: 24461476
[TBL] [Abstract][Full Text] [Related]
20. Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: a prospective, multicenter study.
Daulouède JP; Caer Y; Galland P; Villeger P; Brunelle E; Bachellier J; Piquet JM; Harbonnier J; Leglise Y; Courty P
J Subst Abuse Treat; 2010 Jan; 38(1):83-9. PubMed ID: 19800758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
